|
|
 |
|
Viewing report
|
|
|
|
sanofi-aventis - Pipeline - Products - Performance - Potential
Espicom Business Intelligence Ltd, Nov 2010, Pages: 222
The merger of Sanofi-Synthélabo and Aventis in August 2004, created the world's third largest research-based pharmaceutical company behind Pfizer and GlaxoSmithKline. It has subsequently been overtaken by Novartis, pushing it to fourth largest overall, but sanofi-aventis can be truly classed as a global company with a worldwide sales and marketing infrastructure.
Many of sanofi-aventis' products are facing patent expiry and declining sales. The addition of semuloparin as a successor to Lovenox, if approved, should partially offset the decline. Alongside a large vaccine R&D pipeline, this may still not be enough to compensate for declining sales of mature products.
The company has a strong position in Europe, particularly the key markets of Germany, France and Italy. In addition, the acquisition of a shareholding in Zentiva in March 2006, reaffirms sanofi-aventis' commitment to emerging Eastern European markets. The acquisition of Aventis in August 2004, also significantly strengthened Sanofi-Synthélabo's position in the US. Aventis also brought with it a significant presence in Latin America.
Of sanofi-aventis' top 15 products, just two recorded strong double-digit growth in 2008 (compared with six in 2006), three recorded moderate single-digit growth (between 5 and 10 per cent) and two recorded low single digit growth. Five products showed a significant decline in sales of more than 10 per cent; Copaxone, Ambien/Myslee/Stilnox, Delix/Tritace, Eloxatin and Nasacort in particular, were hit particularly hard by intense generic competition and the transfer of marketing rights. A further three, Amaryl, Xatral and Allegra also showed single digit declines.
Sanofi Pasteur has the ability to exploit the expanding influenza market and has key agreements with governments to develop and supply vaccine against H5N1 avian influenza and H1N1 'swine' influenza, in the event of a pandemic being declared, once the actual virus strain responsible is identified.
sanofi-aventis has a particularly strong and broad R&D pipeline, particularly in the metabolism/diabetes area. This, together with the potential for further growth in vaccines, means the outlook for sanofi-aventis for the next few years looks very good.
This new strategic analysis report sanofi-aventis: Pipeline, Products, Performance, Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
- Assess the performance of, and risks to, sanofi-aventis' leading launched products.
- Identify sanofi-aventis' key pipeline prospects and assess their potential
- Critically appraise sanofi-aventis' performance at a time of economic challenges
- Review sanofi-aventis' strategic partnerships, M&A activity and financial performance
This new strategic study provides a detailed analysis of sanofi-aventis' competitive position and prospects for he future. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.
|
|
|
|
